Aspira Womens HealthAWHL +3.84%36 FCF Margin % is -18.25% as of Mar. 2026. GuruFocus rates AWHL with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Aspira Womens Health ranks worse than 77.45% on this metric.
The historical rank and industry rank for Aspira Womens Health's FCF Margin % or its related term are showing as below:
AWHL'
s FCF Margin % Range Over the Past 10 Years
Min: -576.23 Med: -299.57 Max: -48.14
Current: -48.14
During the past 13 years, the highest FCF Margin % of Aspira Womens Health was -48.14%. The lowest was -576.23%. And the median was -299.57%.
AWHL's FCF Margin % is ranked worse than 77.45% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.845
vs AWHL: -48.14
Aspira Womens Health FCF Margin % Related Terms
Aspira Womens Health FCF Margin % Historical Data
* Premium members only.
The historical data trend for Aspira Womens Health's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Aspira Womens Health's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Womens Health FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Aspira Womens Health's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Womens Health (AWHL) has a FCF Margin % of -18.25% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Aspira Womens Health and its competitors. According to the industry distribution chart, Aspira Womens Health ranks #158 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 77.5%.
Is Aspira Womens Health's FCF Margin % too high?
Aspira Womens Health's current FCF Margin % is -18.25%. Based on the distribution chart, Aspira Womens Health ranks #158 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Aspira Womens Health has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Womens Health's FCF Margin % compare to BIOQ and MBAI?
According to the Medical Diagnostics & Research industry distribution chart, Aspira Womens Health ranks #158 out of 204 companies for FCF Margin %. This places Aspira Womens Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Aspira Womens Health and its competitors. Aspira Womens Health's current FCF Margin % is -18.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Womens Health stock overvalued right now?
Based on GuruFocus' analysis, Aspira Womens Health (AWHL) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $0.43 — trading 52.1% above its estimated fair value. The current FCF Margin % is -18.25%. Aspira Womens Health's overall GF Score™ is 36/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Aspira Womens Health (AWHL), the current FCF Margin % is -18.25% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspira Womens Health (AWHL) Overvalued in 2026?
Based on GuruFocus' analysis, Aspira Womens Health stock appears to be overvalued.
The current stock price of $0.43 is trading 52.1% above its estimated GF Value™ of $0.28.
GuruFocus considers Aspira Womens Health to be Significantly Overvalued.
Key valuation signals for AWHL:
FCF Margin %: -18.25%
GF Value™: $0.28 vs. price of $0.43 (52.1% above fair value)
No single metric tells the full story. See the AWHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its main products include OvaWatch, Ova1Plus, Ova1, and Overa, which are used to assess ovarian cancer risk in women with adnexal masses. The company is also developing EndoCheck for endometriosis. The company views its operations and manages its business in a single operating segment, which is the discovery, development, and commercialization of noninvasive diagnostic tests.
36GF Score
Get the complete analysis for AWHL
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AWHL has been successfully added to your 
